Deviry

Quick links to important sections

Deviry

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deviry

Property Description
Active ingredient Medroxyprogesterone Acetate (MPA)
Form Tablet
Pharmacological class Progestogen
Common use (General) Management of hormonal imbalance
Origin Synthetic Steroid

What Type of Medicine is Deviry and What is its Active Component?

Deviry is a prescription-only medication that is formally classified as a hormonal drug, with its action centered on the active ingredient, Medroxyprogesterone Acetate (MPA). The drug belongs to the Pharmacological class of Progestogens and functions as a synthetic equivalent of the body's natural progesterone. MPA is a synthetic steroid and a specific Progesterone derivative, which provides it with enhanced stability for oral delivery compared to the unmodified natural hormone. Deviry is clinically recognized for its reliable progestational efficacy across various gynaecological contexts.

Medroxyprogesterone Acetate reliably transforms proliferative into secretory endometrium in women with adequate endogenous estrogen. This structural modification and specific pharmacological activity establish Deviry as a potent single-ingredient product designed to influence the endocrine system precisely, particularly in conditions necessitating controlled hormonal withdrawal.

Deviry's Physical Form and High-Level Action

Deviry is supplied as an oral preparation in a tablet dosage form, formulated for consistent oral administration. The composition (high-level) involves the active MPA compound integrated with necessary solid pharmaceutical excipients (tableting base). Its use is specifically directed toward adult women managing issues of hormonal imbalance.

The medicine’s general purpose is to effectively manage and regulate processes dependent on the reproductive hormonal axis. Its core mechanism principle is the Progestational effect, which involves inducing controlled changes, such as endometrial transformation, essential for stabilizing the menstrual cycle and managing hormonal influence on target tissues. Medroxyprogesterone tablets are frequently used for amenorrhea (unusual stopping of menstrual periods) and abnormal uterine bleeding, reinforcing its primary role in cycle regulation.

Regulatory References

  1. Medroxyprogesterone - StatPearls

What side effects are possible with Deviry?

Possible Side Effects and Safety Information

Deviry (medroxyprogesterone acetate) has a well-defined safety profile based on regulatory documentation. Adverse reactions are classified by frequency and system-organ class.

Common Adverse Reactions

Reactions frequently reported include headache, nausea, weight changes, breast tenderness, and changes in menstrual flow (such as irregular bleeding, spotting, or the absence of a period). Other common effects involve the central nervous system (e.g., nervousness, dizziness) and skin (e.g., acne, hair loss).

Serious and Clinically Significant Adverse Reactions

This medication carries warnings regarding the potential for serious thromboembolic events, including deep vein thrombosis (DVT), pulmonary embolism, and stroke. The risk of heart attack is also documented. Additionally, the risk of developing certain hormone-sensitive cancers, specifically breast, ovarian, and uterine cancers, may be increased with use, especially in combination with estrogen therapy or long-term use. Other serious reactions include jaundice (liver dysfunction) and sudden changes in vision.

Contraindications and Safety Restrictions

Deviry is contraindicated in patients with a history of blood clots/thrombophlebitis, breast cancer, known or suspected liver disease, or undiagnosed abnormal vaginal bleeding. Use is strictly not recommended during pregnancy, as it may cause fetal harm and birth defects. Caution is required in patients with conditions such as asthma, epilepsy, migraines, diabetes, and severe kidney problems. The official labeling notes that the medicine is not a contraceptive; a non-hormonal method of contraception must be used to prevent pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

This information details the officially documented overdose profile and required emergency actions for Medroxyprogesterone Acetate (Deviry), as stated in government regulatory documents.


Documented Overdose Manifestations

Regulatory reporting indicates that Medroxyprogesterone Acetate is generally well tolerated even when taken at oral doses significantly higher than the standard therapeutic range. Acute severe toxicity is not commonly documented as a primary risk of overdose. When overexposure occurs, reported manifestations tend to be non-severe and may include:

  • Gastrointestinal: Nausea, vomiting, abdominal pain.
  • Hormonal/Other: Breast tenderness, dizziness, drowsiness or fatigue, and withdrawal bleeding in women.

Required Emergency Actions

The treatment for Medroxyprogesterone Acetate overdose is explicitly defined in regulatory guidance. Since no specific antidote is known, management consists of discontinuation of the medication followed by the institution of appropriate symptomatic and supportive care.

Immediate medical assistance must be sought, as per official government instructions, if the individual exhibits severe distress following a suspected overdose. Emergency services must be contacted immediately if the person is showing signs of a life-threatening reaction, such as having a seizure, collapsing, or experiencing trouble breathing.

Therapeutic Uses of Deviry

Deviry (medroxyprogesterone acetate or MPA) is a progestin that provides supportive management across various gynecological conditions characterized by periods of heightened symptoms related to the menstrual cycle and the uterus. This medication is commonly used to help with specific conditions, including secondary amenorrhea (the absence of menstrual periods), abnormal uterine bleeding due to hormonal imbalance, and plays a role in managing the risk of endometrial hyperplasia in women receiving estrogen therapy.

This application is relevant when supportive symptom management is appropriate and is applied in addressing symptoms related to systemic imbalance that can be disruptive to daily comfort. This supportive role provides support that helps ease the overall symptom burden during difficult episodes. Furthermore, it may assist with maintaining functional stability related to the reproductive system. Clinicians often look to this therapy when seeking short-term symptomatic assistance.

“This therapy is applied across domains where additional symptomatic support is needed for patients experiencing fluctuating manifestations.”

Quick Fact: Relief for symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

Deviry (Medroxyprogesterone Acetate) is strictly governed by regulatory eligibility rules defined in official documents like the FDA Prescribing Information and the EMA SmPC. Use is limited to adult women being treated for secondary amenorrhea or abnormal uterine bleeding due to hormonal imbalance.

Contraindications: Who Must Not Use Deviry

The medicine is contraindicated in several high-risk patient populations. Use is prohibited in cases of known or suspected pregnancy (categorized as Pregnancy Category X). It is also strictly forbidden for individuals with active thrombophlebitis or a history of thromboembolic disorders (blood clots) or cerebral vascular disease (stroke). Other absolute exclusions include significant liver disease, undiagnosed abnormal vaginal bleeding, and a known or suspected malignancy of the breast or other hormone-dependent cancers.

Population Restrictions

Use is not indicated in pediatric patients (children) as safety and efficacy have not been established. For older adults (65 years and over), caution is required, particularly when combined with estrogen, due to an increased risk of developing probable dementia. Patients with diabetes mellitus or existing risk factors for osteoporosis or vascular disease also require close supervision.

What should I know about interactions with other medicines?

Deviry (medroxyprogesterone acetate) can interact with various other medicines and herbal products, which may alter the effectiveness of Deviry or the concomitant medication, or increase the risk of side effects. It is essential to inform your healthcare provider about all prescription and over-the-counter drugs, vitamins, and herbal supplements you are taking.

Medications That May Decrease Deviry's Effectiveness

Certain drugs can increase the rate at which the body processes Deviry, leading to lower concentrations of the progestin in the blood and potentially reduced efficacy. This is particularly important if Deviry is being used for contraception, as its effectiveness could be compromised. Examples include:

  • Anticonvulsants/Antiepileptics: Such as phenobarbital, phenytoin, and carbamazepine.
  • Antibiotics: Including rifampicin.
  • HIV/AIDS Medications: Certain protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
  • Other Drugs: Aminoglutethimide.

Other Potential Interactions

Deviry may affect the action of certain other medications and laboratory tests:

Type of Product Examples of Interaction Potential Outcome
Herbal Supplements St. John’s Wort May decrease Deviry's effectiveness.
Anticoagulants Warfarin Deviry may affect blood clotting tests.
Lab Tests Thyroid, liver function, and coagulation tests May interfere with results, leading to false readings.

Co-administration of Deviry with estrogens may increase the risk of conditions like stroke, deep vein thrombosis, and myocardial infarction, especially in postmenopausal women. Always consult with your doctor before starting or stopping any new product.

Mechanism of Action

Deviry (medroxyprogesterone acetate or MPA) is a synthetic progestin that acts by engaging and modulating key hormone-responsive pathways to produce specific physiological changes.

The primary mechanism is centered on its action as a Progesterone Receptor (PR) agonist. This molecular interaction alters gene transcription in target cells, initiating a premature secretory transformation of the endometrium, which establishes a non-proliferative state.

MPA also exerts negative feedback on the Hypothalamic-Pituitary-Ovarian (HPO) Axis. This central action suppresses the cyclical release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) from the pituitary, leading directly to the inhibition of ovulation (anovulation).

Furthermore, the drug produces direct peripheral physiological changes. It causes the endometrium to thin and the cervical mucus to become thicker and less permeable, physically altering the environment of the upper reproductive tract.

Dosage and Administration Information

Deviry, which contains the progestogen Medroxyprogesterone Acetate, is administered via the oral route using tablet dosage forms, typically available in strengths of 2.5 mg, 5 mg, and 10 mg. The medicine is used on a standardized, cyclic schedule determined by the indication being managed.

For approved conditions like secondary amenorrhea and abnormal uterine bleeding, the prescribed dose is typically 5 mg or 10 mg taken once daily for a finite period of 5 to 10 consecutive days. The complete administration is designed as a short course, which is often repeated for two to three consecutive cycles as necessary to regulate the endocrine process.

The daily tablet should be taken at the same time each day, as administration with food increases the bioavailability of the active component. Specific protocols govern the commencement of the course: when used for abnormal uterine bleeding, the regimen advises beginning the course on the calculated 16th or 21st day of the menstrual cycle. If a daily dose is forgotten, the standard procedure is to skip the missed dose if it is close to the time for the next dose, and never to take two doses simultaneously. Following the final dose of the course, progestin withdrawal bleeding is usually expected to occur within three to seven days. Use is not recommended in pediatric patients.

Recent Clinical Evidence

Research evidence / Overview of studies for Deviry

Evidence for Use in Regulating the Menstrual Cycle (Amenorrhea and Abnormal Bleeding)

The research concerning the use of this drug in women experiencing the absence of menstruation, known as amenorrhea, or abnormal uterine bleeding includes primarily observational studies and analyses of patient data. These studies have explored the research context involving adult populations experiencing these conditions when the patterns are related to systemic or functional hormonal imbalance.

Studies monitored outcomes reflecting daily functioning and activity level, as well as patient-reported outcomes linked to irregular cycles. Findings described measured patterns related to changes in menstruation during the study period. What remains uncertain is the long-term stability of the menstrual cycle after the treatment is complete, as follow-up durations were limited in many reports.

Evidence for Use in Managing Endometriosis

Research examining the use of this drug in adult populations diagnosed with endometriosis has included clinical trials and longer-term cohort studies. These studies have explored adult women with a confirmed diagnosis, focusing on outcomes related to physical discomfort, such as pain scores, and measurements reflecting disease activity. Some research highlighted the measurement of outcomes related to physical discomfort. However, comparative evidence is lacking in some areas, and long-term effects are not fully established on the potential recurrence of symptoms.

Long-term Studies and Follow-up

Research has also explored the extended effects of this drug, often through observational cohorts and post-marketing surveillance. These studies have monitored patient outcomes over several years, well beyond the short-term treatment period. These long-term studies have tracked outcomes related to bone health and patterns related to systemic or functional imbalance. Findings also describe patterns related to changes in reproductive measures after stopping the drug. Crucially, there is limited information for long-term outcomes over many decades, and research does not determine whether an individual will respond similarly over the full course of their lifetime.

Key Studies & References

  1. Systematic Review of Progestin-Based Therapies for Chronic Abnormal Uterine Bleeding

Frequently Asked Questions (FAQ)

Common questions about Deviry (FAQ)

Q: Is Deviry the same as other progesterone medicines?

Deviry contains Medroxyprogesterone Acetate (MPA), which is a synthetic progestin. This means it is a man-made substance designed to act like the body's natural progesterone. Official product information notes that MPA is structurally different from the natural hormone and other synthetic progesterone-like drugs.


Q: Can Deviry affect my mood or cause anxiety?

Yes, official regulatory labels list depression, anxiety, insomnia (trouble sleeping), nervousness, and irritability as possible adverse reactions. Any significant changes in mood should be brought to the attention of a healthcare provider.


Q: Does Deviry cause weight gain or water retention?

Regulatory documents list both weight gain and edema (fluid retention or swelling) as possible common adverse reactions. These effects are recognized and documented in the official product information.


Q: Is it normal to feel tired when taking Deviry?

Official information lists fatigue and asthenia (a lack of energy or weakness) as possible common side effects. If fatigue is extreme or persistent, it is advisable to consult with a healthcare provider.


Q: Can Deviry be taken with pain relievers like ibuprofen?

Formal interaction studies with over-the-counter pain relievers like ibuprofen are generally not detailed in regulatory documents, and no specific contraindication is noted. However, consultation with a healthcare provider is recommended to review all concomitant medications, including pain relievers.


Q: Are there any foods or drinks I should avoid while on Deviry?

Official product information notes that taking the tablet with food increases the body's absorption of the active ingredient. However, official sources do not list specific foods or drinks that must be strictly avoided while taking this medication.


Q: Does alcohol interact with Deviry?

There is typically no specific interaction between Medroxyprogesterone Acetate and alcohol reported in major regulatory documents. Discussing alcohol intake with a healthcare provider is generally recommended when starting any new medication.


Q: What happens if I forget to take a dose of Deviry?

Official regulatory guidance advises that if a daily dose is missed, you should skip the missed dose if it is close to the time for the next dose. It is strictly advised that you never take two doses simultaneously to make up for the missed one.


Q: Will Deviry delay my period?

Deviry is designed to regulate the menstrual cycle, and its action on the uterus often leads to a scheduled withdrawal bleed after the course is finished. Regulatory labels list amenorrhea (absence of periods) and general changes in menstrual flow as possible side effects.


Q: Can Deviry be used by women who are not menopausal?

Yes, Deviry is indicated for use in adult women for the treatment of secondary amenorrhea and abnormal uterine bleeding. These conditions, which are due to a hormonal imbalance, can affect women who are still in their reproductive years.


Q: Is Deviry safe for teenagers with irregular periods?

Official regulatory labeling explicitly states that Medroxyprogesterone Acetate is not indicated in pediatric patients and that its safety and effectiveness have not been established in this younger population.


Q: Why would a doctor prescribe Deviry for abnormal uterine bleeding?

A doctor would prescribe this medication because its active ingredient acts as a Progesterone Receptor (PR) agonist. This action induces a controlled, secretory transformation of the endometrium (the lining of the uterus), helping to resolve abnormal bleeding caused by hormonal imbalance.


Q: Is it normal to have spotting while taking Deviry?

Spotting (light bleeding) and breakthrough bleeding are specifically listed in regulatory documents as common adverse reactions. This means that having spotting during the course of treatment is a recognized and documented side effect.


Q: Can Deviry interfere with thyroid medication?

While regulatory documents do not list a direct interaction with the thyroid medication itself, they do note that Medroxyprogesterone Acetate can interfere with the results of thyroid function tests. It is important for a healthcare provider to be aware of the medication use when evaluating thyroid function test results.


Q: What are the signs of a serious reaction to Deviry?

Serious reactions are rare but possible. Official information lists symptoms such as sudden severe headache, vision changes, pain or swelling in the legs (a sign of a blood clot), jaundice (yellowing of the skin), and shortness of breath as potential signs. Seeking emergency medical attention is necessary if any signs of a serious reaction are experienced.


Q: Do I need a prescription to buy Deviry?

Yes, regulatory authorities classify Medroxyprogesterone Acetate tablets as a prescription-only medication. It requires a valid prescription from a licensed healthcare provider to be dispensed.


Q: Can men take Deviry for any reason?

No, the approved indications for Deviry (MPA tablets) are strictly limited to adult women for the treatment of gynaecological conditions. Its use is not indicated for any condition in men.


Q: Does taking Deviry change my chances of getting pregnant later?

The drug is not a contraceptive, and reproductive function usually returns after the course is completed. Regulatory follow-up studies have tracked changes in reproductive measures after stopping the drug, but there is no definitive statement from official sources regarding long-term fertility or the chances of getting pregnant later.


Q: Is Deviry used to treat endometriosis?

Yes, regulatory labels confirm that Medroxyprogesterone Acetate is indicated for the management of endometriosis. This is one of the conditions for which the drug has approved use.


Q: Can Deviry cause changes in hair growth?

Regulatory documents list both hair loss (alopecia) and hirsutism (an increase in body or facial hair growth) as possible adverse reactions. If unwanted or significant changes in hair growth are noticed, consultation with a healthcare provider is recommended.


Q: Is it okay to stop taking Deviry suddenly?

The medication is typically prescribed as a short, fixed course (e.g., 5 to 10 days). While the official guidance notes that the expected bleeding will occur after the last dose, stopping the course prematurely may prevent the desired therapeutic effect. Any decision to alter or stop the course of treatment should be discussed with a healthcare provider.


Q: What is the maximum duration of treatment with Deviry?

For its labeled uses (like amenorrhea), the typical treatment course is 5 to 10 consecutive days, sometimes repeated for a few cycles. However, regulatory warnings exist regarding increased risks associated with prolonged or long-term use for certain populations, highlighting that a healthcare provider should determine the appropriate duration for individual treatment.


Q: Can Deviry be taken by someone with high blood pressure?

Regulatory labels advise that risk factors for serious conditions like arterial vascular disease, which include hypertension (high blood pressure), should be managed before and during treatment. The drug should be used with caution in patients with these pre-existing risk factors.


Q: What should I do if I accidentally take two Deviry tablets?

In the event of an accidental overdose or if you take more Deviry than prescribed, the official guidance is that emergency medical attention should be sought immediately.


Q: Can Deviry make an existing medical condition worse?

Caution is specifically advised in patients with certain pre-existing conditions, including asthma, epilepsy, migraines, and diabetes, as the drug may have an impact on the management of these conditions.


Q: Are there generic versions of Deviry available?

Yes, Medroxyprogesterone Acetate tablets are widely available. Regulatory documents confirm that generic versions are available from various manufacturers and are considered therapeutically equivalent to the brand-name product.


Q: How does Deviry compare to natural progesterone supplements?

Deviry contains Medroxyprogesterone Acetate, which is a synthetic progestin (a man-made form of the hormone). Regulatory texts note that its synthetic structure gives it enhanced stability for effective oral delivery compared to the unmodified natural hormone.


Q: Is it true that Deviry is used for fibroids?

Deviry is officially indicated to treat abnormal uterine bleeding that is caused by hormonal imbalance. It is not indicated for treating bleeding that results from structural issues, such as uterine fibroids or uterine cancer.


Q: What's the difference between Deviry and progestin-only birth control pills?

Both contain a progestin, but they have different official uses. Deviry (MPA tablets) is approved for the treatment of gynaecological conditions and is not indicated or approved as a contraceptive. Progestin-only pills are specifically indicated for preventing pregnancy.


Q: What should I do if I experience unexpected bleeding while on Deviry?

While spotting is a common side effect, if the abnormal bleeding persists or becomes severe, regulatory guidelines indicate that the possibility of a more serious medical issue (organic pathology) must be ruled out. Prompt consultation with a healthcare provider is necessary for an appropriate evaluation.

How should Deviry be stored and disposed of?

Storage and Disposal of Deviry

Deviry (Medroxyprogesterone Acetate) tablets must be stored according to regulatory requirements to ensure product integrity and safety.

Storage Requirement Specification
Temperature Range Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection Store in a tightly closed container and protect from moisture.
Safety Keep the medication out of the reach of children.

Storage outside of the specified temperature range, including excessive heat or freezing, must be avoided. When disposing of unused or expired tablets, official guidelines recommend utilizing a drug take-back program. If a take-back program is unavailable, the tablets should be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. The tablets must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Deviry found in:

A-Z Index: